We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$224K
AUM Growth
-$183M
Cap. Flow
+$30.6M
Cap. Flow %
13,629.74%
Top 10 Hldgs %
33.66%
Holding
127
New
36
Increased
38
Reduced
22
Closed
31

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.26M
2
MGNX icon
MacroGenics
MGNX
+$5.18M
3
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.94M
4
VCYT icon
Veracyte
VCYT
+$3.89M
5
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$3.65M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$6.78M
2
CRIS icon
Curis
CRIS
+$4.17M
3
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$4.01M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$3.36M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 79.44%
2 Financials 6.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
101
Biogen
BIIB
$30.4B
– –
-5,000
Closed -$1.4M
BLRX
102
BioLineRX
BLRX
$12.2M
– –
-5,000
Closed -$558K
CHRS icon
103
Coherus Oncology
CHRS
$222M
– –
-100,000
Closed -$1.46M
CLRB icon
104
Cellectar Biosciences
CLRB
$20M
– –
-2,021
Closed -$976K
EPIX
105
DELISTED
ESSA Pharma
EPIX
– –
-73,451
Closed -$2.13M
FULC icon
106
Fulcrum Therapeutics
FULC
$248M
– –
-121,302
Closed -$1.43M
IMVT icon
107
Immunovant
IMVT
$7.99B
– –
-50,400
Closed -$808K
KALA icon
108
KALA BIO
KALA
$12.3M
– –
-41
Closed -$689K
CYPH
109
Cypherpunk Technologies Inc
CYPH
$65.4M
– –
-30,000
Closed -$570K
LRMR icon
110
Larimar Therapeutics
LRMR
$398M
– –
-191,945
Closed -$2.8M
SLNO
111
DELISTED
Soleno Therapeutics
SLNO
– –
-8,333
Closed -$158K
SRRK icon
112
Scholar Rock
SRRK
$5.92B
– –
-36,221
Closed -$1.83M
TVTX icon
113
Travere Therapeutics
TVTX
$5.2B
– –
-20,000
Closed -$499K
VCEL icon
114
Vericel Corp
VCEL
$2.39B
– –
-122,125
Closed -$6.78M
VRTX icon
115
Vertex Pharmaceuticals
VRTX
$124B
– –
-7,500
Closed -$1.61M
WVE icon
116
CALL
Wave Life Sciences
WVE
$1.13B
– –
-100,000
Closed -$561K
PVLA
117
Palvella Therapeutics
PVLA
$2.05B
– –
-625
Closed -$129K
VIRX
118
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-28,570
Closed -$264K
GMDA
119
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-23,393
Closed -$189K
PNT
120
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-40,000
Closed -$420K
ISEE
121
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-130,043
Closed -$804K
ONCR
122
DELISTED
Oncorus, Inc.
ONCR
– –
-130,000
Closed -$1.81M
RXDX
123
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-15,000
Closed -$274K
APTO
124
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-222
Closed -$598K
CCXI
125
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-55,974
Closed -$1.38M
2 3 4
5
6

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Silverarc Capital Management held 127 positions worth $224K, down 100% from $183M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Silverarc Capital Management deployed $30.6M of net new capital in Q2 2021, opening 36 new positions and adding to 38 existing holdings. Its largest new stake was MacroGenics: 176,915 shares worth $4.75K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 86% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Curis, an estimated $4.17M trimmed.

  • Silverarc Capital Management's largest Q2 2021 buy was MacroGenics: 176,915 shares worth $4.75K.
  • Silverarc Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $5.26M increase.
  • Silverarc Capital Management's biggest Q2 2021 reduction was Curis, cutting an estimated $4.17M.
  • Silverarc Capital Management fully exited Vericel Corp in Q2 2021, selling an estimated $6.78M.
  • Silverarc Capital Management's ten largest holdings make up 34% of its $224K portfolio in Q2 2021.
  • Silverarc Capital Management opened 36 new positions and closed 31 in Q2 2021.
  • Silverarc Capital Management's portfolio value fell 100% quarter-over-quarter to $224K.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.